4Q21: Eli Lilly & Co. reported earnings of $2.49/share, exceeding analysts' expectations by $0.19.
4Q21: Eli Lilly & Co. saw several institutional investors adjust their positions, with AltFest L J & Co. Inc. reducing its stake by 3.9% while Procyon Advisors LLC increased its by 15.5%. The company reported earnings of $2.49/share for Q4, exceeding analysts' expectations by $0.19. Equities research analysts have given the company a consensus rating of "Moderate Buy" and an average price target of $689.52.
March 27, 2024
8 Articles